USF1
Basic information
Region (hg38): 1:161039250-161045977
Links
Phenotypes
GenCC
Source:
- hyperlipidemia, combined, 1 (Limited), mode of inheritance: AD
ClinVar
This is a list of variants' phenotypes submitted to
- Inborn genetic diseases (4 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the USF1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 3 | |||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region ? | 1 | 1 | ||||
non coding ? | 0 | |||||
Total | 0 | 0 | 3 | 0 | 0 |
Variants in USF1
This is a list of pathogenic ClinVar variants found in the USF1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
1-161039733-G-A | Hyperlipidemia, familial combined, susceptibility to | risk factor (Sep 01, 2005) | ||
1-161039928-T-C | not specified | Uncertain significance (Nov 21, 2022) | ||
1-161040209-C-A | not specified | Uncertain significance (Dec 30, 2023) | ||
1-161040229-C-G | not specified | Uncertain significance (Mar 06, 2023) | ||
1-161040251-A-G | not specified | Uncertain significance (Jun 03, 2022) | ||
1-161040573-G-A | not specified | Uncertain significance (Jul 26, 2023) | ||
1-161040972-C-T | Hyperlipidemia, familial combined, susceptibility to | risk factor (Sep 01, 2005) | ||
1-161041352-T-C | not specified | Uncertain significance (Jan 09, 2024) | ||
1-161041845-G-A | not specified | Uncertain significance (Jan 19, 2024) | ||
1-161042154-C-T | not specified | Uncertain significance (Nov 29, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
USF1 | protein_coding | protein_coding | ENST00000368021 | 10 | 6727 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0235 | 0.976 | 125325 | 0 | 423 | 125748 | 0.00168 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.14 | 107 | 190 | 0.563 | 0.0000113 | 2006 |
Missense in Polyphen | 27 | 63.998 | 0.42189 | 692 | ||
Synonymous | 0.107 | 70 | 71.2 | 0.984 | 0.00000411 | 620 |
Loss of Function | 3.02 | 7 | 22.5 | 0.312 | 0.00000136 | 208 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00732 | 0.00699 |
Ashkenazi Jewish | 0.000701 | 0.000695 |
East Asian | 0.000771 | 0.000761 |
Finnish | 0.00291 | 0.00287 |
European (Non-Finnish) | 0.00182 | 0.00179 |
Middle Eastern | 0.000771 | 0.000761 |
South Asian | 0.0000656 | 0.0000653 |
Other | 0.00282 | 0.00277 |
dbNSFP
Source:
- Function
- FUNCTION: Transcription factor that binds to a symmetrical DNA sequence (E-boxes) (5'-CACGTG-3') that is found in a variety of viral and cellular promoters.;
- Disease
- DISEASE: Hyperlipidemia combined 1 (HYPLIP1) [MIM:602491]: A disorder characterized by a variable pattern of elevated levels of serum total cholesterol, triglycerides or both. It is observed in a percentage of individuals with premature coronary heart disease. {ECO:0000269|PubMed:14991056}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.;
- Pathway
- Signal Transduction;Signaling by Nuclear Receptors;Estrogen-dependent gene expression;ESR-mediated signaling;Signaling mediated by p38-alpha and p38-beta
(Consensus)
Recessive Scores
- pRec
- 0.637
Intolerance Scores
- loftool
- 0.273
- rvis_EVS
- -0.41
- rvis_percentile_EVS
- 26.23
Haploinsufficiency Scores
- pHI
- 0.298
- hipred
- Y
- hipred_score
- 0.735
- ghis
- 0.630
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 1.00
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Usf1
- Phenotype
- nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);
Gene ontology
- Biological process
- regulation of transcription from RNA polymerase II promoter by glucose;positive regulation of transcription from RNA polymerase II promoter by glucose;response to hypoxia;glucose metabolic process;regulation of transcription by RNA polymerase II;transcription by RNA polymerase II;response to UV;late viral transcription;cellular response to insulin stimulus;glucose homeostasis;positive regulation of transcription by RNA polymerase II;carbon catabolite regulation of transcription;negative regulation of fibrinolysis;lipid homeostasis
- Cellular component
- nuclear chromatin;nucleus;nucleoplasm;transcription factor complex;NURF complex;Set1C/COMPASS complex
- Molecular function
- DNA-binding transcription factor activity, RNA polymerase II-specific;double-stranded DNA binding;protein binding;enzyme binding;protein kinase binding;identical protein binding;protein homodimerization activity;histone deacetylase binding;bHLH transcription factor binding;sequence-specific DNA binding;protein heterodimerization activity